TBPH News & Events

Reports Q1 revenue $17.7M, consensus $17.45M. "We delivered strong financial performance in the first quarter, reinforcing the quality of our commercial asset, our robust balance sheet and the important actions underway to reshape our cost structure, following the outcome of the CYPRESS study," said CEO Rick Winningham. "YUPELRI continues to deliver sustained net sales growth and expanding profitability, supported by growing community and hospital adoption, improved net pricing, and the recent resolution of generic litigation, driving increased long-term value for the franchise. TRELEGY also continued to perform well, and we remain confident that we will achieve the $100M milestone payment associated with 2026 net sales. The entire Theravance team is acting with discipline and urgency, and we are confident that the continued execution against our strategic priorities and the Board's ongoing review process will maximize value for shareholders."

Reports Q4 revenue $45.891M, consensus $50.7M. "We ended 2025 on a positive note from a financial perspective, achieving another record quarter of non-GAAP profitability, hitting a new all-time high for Yupelri brand-level profitability, and reaching $75 million in key sales-based milestones. These results highlight the strength and durability of our commercial asset, Yupelri, our commitment to operating with financial and operational discipline, and the strength of our balance sheet," said Rick E Winningham, Chief Executive Officer of Theravance Biopharma. "Since announcing the CYPRESS study results earlier this month, we have made progress implementing an organizational restructuring to streamline costs and align resources with the commercial opportunity ahead of Yupelri, We are confident that these actions, paired with the important work that the Board's Strategic Review Committee is doing to evaluate opportunities available to the Company, will enable Theravance to deliver on our goal of maximizing value for shareholders."